HKG:2526

2 stories mentioning HKG:2526Updated 32d ago

Every FINWIRES story that references HKG:2526, newest first.

Diagens Biotechnology's Chromosome Analysis Device Gets Registration Certificate in China

Hangzhou Diagens Biotechnology's (HKG:2526) core product AI AutoVision obtained a Class III Medical Device Registration Certificate from China's National Medical Products Administration, according to a Friday filing with the Hong Kong bourse.The approved indications under the certificate cover chromosome karyotype analysis for the prenatal diagnosis for birth defects using amniotic fluid samples and assisted reproduction using peripheral blood samples.

HKG:2526

Asia55d ago

Diagens Biotechnology's 2025 Loss Widens

Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.

HKG:2526

Track with the FINWIRES app suite

FolioX

Track HKG:2526 in your portfolio

WheelAI

Analyze HKG:2526 options with the wheel strategy

StockInsider

See market sentiment on HKG:2526